AzTrials
AzTrials

Medical ImagingNR SpectralNCT07305103

Defining Dosimetric Reference Levels in Computed Tomography Spectral Scanning

An observational study of Medical Imaging, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Spectral computed tomography or dual-energy CT imaging can overcome the limitations of conventional CT in differentiating between two materials with equivalent total attenuation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Medical Imaging
What is being tested?
Spectral ComputedTomography
How many people
9,600 participants
Where
1 siteFrance
Study dates
1 Sep 2025to 30 Jun 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All adult patients who underwent a spectral CT scan between January 1, 2023, and August 31, 2024, as part of their treatment.

Who may be able to join

  • Adult male/female patient (≥ 18 years old)
  • Body Mass Index (BMI) between 18 and 35 kg/m²
  • Patients who underwent a spectral CT scan between January 1, 2023, and August 31, 2024, as part of their treatment.

Who cannot join

  • Pregnant women

Trial locations and contacts

1 site in 1 country.

France1 site

  • Nîmes University Hospital

    Nîmes, Gard, 30029

Other trials in France

About this study

Spectral computed tomography or dual-energy CT imaging can overcome the limitations of conventional CT in differentiating between two materials with equivalent total attenuation. It can generate several types of images, such as virtual monochromatic images, which improve the contrast-to-noise ratio for low energy levels and reduce artifacts for high energy levels. It also allows for quantitative image analysis and thus better characterization of lesions and tissues through material mapping (e.g., iodinated contrast agent mapping). This technique is increasingly used in routine clinical practice thanks to improvements in image flow management and technological advances. It also involves exposing patients to ionizing radiation, as with conventional CT but, unlike conventional CT scans, for which dosimetric reference levels (RLs) are defined for the most common examinations in France (RL decree dated 2019), there are currently no dosimetric reference levels for examinations performed using this technique. Yet RLs are an important and effective tools for optimizing patient exposure to ionizing radiation. Several articles were published between 2012 and 2017 when the first dual-energy scanners arrived in clinics. However, the results presented in these studies are now far removed from recent practices, as they do not take into account the latest technological developments used in dual-energy scanners, which reduce X-ray doses.

The main objective of the study is to define dosimetric reference levels for the most commonly performed spectral computed tomography examinations in France.

Read the detailed description

Spectral computed tomography (CT) (or dual-energy CT) imaging can overcome the limitations of conventional CT in differentiating between two materials with equivalent total attenuation. It can generate several types of images, such as virtual monochromatic images, which improve the contrast-to-noise ratio for low energy levels and reduce artifacts for high energy levels. It also allows for quantitative image analysis and thus better characterization of lesions and tissues through material mapping (e.g., iodinated contrast agent mapping). This technique is increasingly used in routine clinical practice thanks to improvements in image flow management and technological advances. It also involves exposing patients to ionizing radiation, as with conventional CT.

However, unlike conventional CT scans, for which dosimetric reference levels (RLs) are defined for the most common examinations in France (RL decree dated 2019), there are currently no dosimetric reference levels for examinations performed using this technique. Yet the RL is an important and effective tool in optimizing patient exposure to ionizing radiation. In fact, a number of articles were published between 2012 and 2017, when the first dual-energy scanners arrived in clinics. However, the results presented in these studies are now far removed from recent practices, as they do not take into account the latest technological developments used in dual-energy scanners, which reduce X-ray doses.

The main objective of the study is to define dosimetric reference levels for the most frequently performed spectral computed tomography examinations in France:

  1. Chest CT for pulmonary embolism
  2. Chest CT for other indications
  3. Coronary CT with contrast injection and retrospective gating
  4. Coronary CT with contrast injection and prospective gating
  5. Cranial CT with contrast injection
  6. Supra-aortic trunk CT
  7. Neck and ear,nose and throat sphere CT with contrast injection
  8. Oncological abdomen-pelvis CT scan
  9. Abdomen-pelvis CT scan to check for kidney stones
  10. Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones
  11. Oncological chest-abdomen-pelvis CT scan
  12. Non-oncological chest-abdomen-pelvis CT scan
  13. Oncological chest-abdomen CT scan
  14. Non-oncological chest-abdomen CT scan
  15. Lower limb angiography
  16. Cervical spine CT scan
  17. Thoracic spine CT scan
  18. Lumbar spine CT scan
  19. Pelvis CT scan,
  20. Extremities CT scan

The secondary objectives of the study are to evaluate, for each examination performed:

  1. the impact of the spectral acquisition/detection technique on the dose delivered to patients.
  2. the impact of patients' BMI on the dose delivered to patients.
  3. the impact of reconstruction algorithms on the dose delivered to patients.
Conditions
Medical Imaging
Being tested
Spectral ComputedTomography
Keywords
Radiation dose, Reference levels, Radiology, Spectral Computed Tomography Imaging

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Spectral ComputedTomographyRadiation

    Commonly performed spectral computed tomography examinations in France

Study groups in NCT07305103
Study groupRoleWhat they receive
Patients undergoing a maximum number of 18 spectral CT scans among the examinations mentioned belowPatients undergoing a maximum number of 18 spectral CT scans among the examinations mentioned below: 1. Chest CT for pulmonary embolism 2. Chest CT for other indications 3. Coronary CT with contrast injection and retrospective gating 4. Coronary CT with contrast injection and prospective gating 5. Cranial CT with contrast injection 6. Supra-aortic trunk CT 7. Neck and ear,nose and throat sphere CT with contrast injection 8. Oncological abdomen-pelvis CT scan 9. Abdomen-pelvis CT scan to check for kidney stones 10. Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones 11. Oncological chest-abdomen-pelvis CT scan 12. Non-oncological chest-abdomen-pelvis CT scan 13. Oncological chest-abdomen CT scan 14. Non-oncological chest-abdomen CT scan 15. Lower limb angiography 16. Cervical spine CT scan 17. Thoracic spine CT scan 18. Lumbar spine CT scan 19. Pelvis CT scan, 20. Extremities CT scan
Receives: Radiation: Spectral ComputedTomography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dosimetric reference levels for spectral computed tomography examinations in France: Chest CT for pulmonary embolism. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  2. Dosimetric reference levels for spectral computed tomography examinations in France: Chest CT for pulmonary embolism. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  3. Dosimetric reference levels for spectral computed tomography examinations in France: Chest CT for other indications. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  4. Dosimetric reference levels for spectral computed tomography examinations in France: Chest CT for other indications. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  5. Dosimetric reference levels for spectral computed tomography examinations in France: Coronary CT with contrast injection and retrospective gating. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  6. Dosimetric reference levels for spectral computed tomography examinations in France: Coronary CT with contrast injection and prospective gating. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  7. Dosimetric reference levels for spectral computed tomography examinations in France: Cranial CT with contrast injection. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  8. Dosimetric reference levels for spectral computed tomography examinations in France: Cranial CT with contrast injection. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  9. Dosimetric reference levels for spectral computed tomography examinations in France: Supra-aortic trunk CT. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  10. Dosimetric reference levels for spectral computed tomography examinations in France: Supra-aortic trunk CT. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  11. Dosimetric reference levels for spectral computed tomography examinations in France: Neck and ear,nose and throat sphere CT with contrast injection. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  12. Dosimetric reference levels for spectral computed tomography examinations in France: Neck and ear,nose and throat sphere CT with contrast injection. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  13. Dosimetric reference levels for spectral computed tomography examinations in France: Oncological abdomen-pelvis CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  14. Dosimetric reference levels for spectral computed tomography examinations in France: Oncological abdomen-pelvis CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  15. Dosimetric reference levels for spectral computed tomography examinations in France: Abdomen-pelvis CT scan to check for kidney stones. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  16. Dosimetric reference levels for spectral computed tomography examinations in France: Abdomen-pelvis CT scan to check for kidney stones. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  17. Dosimetric reference levels for spectral computed tomography examinations in France: Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  18. Dosimetric reference levels for spectral computed tomography examinations in France: Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  19. Dosimetric reference levels for spectral computed tomography examinations in France: Oncological chest-abdomen-pelvis CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  20. Dosimetric reference levels for spectral computed tomography examinations in France: Oncological chest-abdomen-pelvis CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  21. Dosimetric reference levels for spectral computed tomography examinations in France: Non-oncological chest-abdomen-pelvis CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  22. Dosimetric reference levels for spectral computed tomography examinations in France: Non-oncological chest-abdomen-pelvis CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  23. Dosimetric reference levels for spectral computed tomography examinations in France: Oncological chest-abdomen CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  24. Dosimetric reference levels for spectral computed tomography examinations in France: Oncological chest-abdomen CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  25. Dosimetric reference levels for spectral computed tomography examinations in France: Non-oncological chest-abdomen CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  26. Dosimetric reference levels for spectral computed tomography examinations in France: Non-oncological chest-abdomen CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  27. Dosimetric reference levels for spectral computed tomography examinations in France: Lower limb angiography. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  28. Dosimetric reference levels for spectral computed tomography examinations in France: Lower limb angiography. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  29. Dosimetric reference levels for spectral computed tomography examinations in France: Cervical spine CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  30. Dosimetric reference levels for spectral computed tomography examinations in France: Cervical spine CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  31. Dosimetric reference levels for spectral computed tomography examinations in France: Thoracic spine CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  32. Dosimetric reference levels for spectral computed tomography examinations in France: Thoracic spine CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  33. Dosimetric reference levels for spectral computed tomography examinations in France: Lumbar spine CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  34. Dosimetric reference levels for spectral computed tomography examinations in France: Lumbar spine CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  35. Dosimetric reference levels for spectral computed tomography examinations in France: Pelvis CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  36. Dosimetric reference levels for spectral computed tomography examinations in France: Pelvis CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm

    Measured: Periprocedural

  37. Dosimetric reference levels for spectral computed tomography examinations in France: Extremities CT scan. CTDIvol

    Computed tomography dose index (CTDIvol) per acquisition expressed in milligray (mGy).

    Measured: Periprocedural

  38. Dosimetric reference levels for spectral computed tomography examinations in France: Extremities CT scan. DLP

    Dose length product (DLP) expressed in mGy.cm will be recorded

    Measured: Periprocedural

Secondary outcomes (183)

  1. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Chest CT for pulmonary embolism. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  2. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Chest CT for pulmonary embolism. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  3. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Chest CT for pulmonary embolism. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  4. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Chest CT for pulmonary embolism. DLP

    Dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  5. Impact of patients' BMI on the dose delivered to patients: Chest CT for pulmonary embolism. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  6. Impact of patients' BMI on the dose delivered to patients: Chest CT for pulmonary embolism. Acquisition parameters, kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  7. Impact of patients' BMI on the dose delivered to patients: Chest CT for pulmonary embolism. Acquisition parameters, mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  8. Impact of patients' BMI on the dose delivered to patients: Chest CT for pulmonary embolism. Acquisition parameters. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  9. Impact of patients' BMI on the dose delivered to patients: Chest CT for pulmonary embolism. Acquisition parameters. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  10. Impact of reconstruction algorithms on the dose delivered to patients : Chest CT for pulmonary embolism. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  11. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Chest CT for other indications. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  12. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Chest CT for other indications. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  13. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Chest CT for other indications. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  14. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Chest CT for other indications. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  15. Impact of patients' BMI on the dose delivered to patients: Chest CT for other indications. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  16. Impact of patients' BMI on the dose delivered to patients: Chest CT for other indications. Acquisition parameters, kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  17. Impact of patients' BMI on the dose delivered to patients: Chest CT for other indications. Acquisition parameters, mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  18. Impact of patients' BMI on the dose delivered to patients: Chest CT for other indications. Acquisition parameters, rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  19. Impact of patients' BMI on the dose delivered to patients: Chest CT for other indications. Acquisition parameters, helical pitch

    Helical pitch time will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  20. Impact of reconstruction algorithms on the dose delivered to patients : Chest CT for other indications. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  21. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Coronary CT with contrast injection and retrospective gating. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  22. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Coronary CT with contrast injection and retrospective gating. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  23. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Coronary CT with contrast injection and retrospective gating. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  24. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Coronary CT with contrast injection and retrospective gating. DLP

    The dose length product (DLP) will be recorded.

    Measured: Periprocedural

  25. Impact of patients' BMI on the dose delivered to patients : Coronary CT with contrast injection and retrospective gating. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  26. Impact of patients' BMI on the dose delivered to patients : Coronary CT with contrast injection and retrospective gating. Acquisition parameters, kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  27. Impact of patients' BMI on the dose delivered to patients : Coronary CT with contrast injection and retrospective gating. Acquisition parameters, mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  28. Impact of patients' BMI on the dose delivered to patients : Coronary CT with contrast injection and retrospective gating. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  29. Impact of patients' BMI on the dose delivered to patients : Coronary CT with contrast injection and retrospective gating. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  30. Impact of reconstruction algorithms on the dose delivered to patients : Coronary CT with contrast injection and retrospective gating. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  31. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Cranial CT with contrast injection. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  32. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Cranial CT with contrast injection. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  33. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Cranial CT with contrast injection. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  34. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Cranial CT with contrast injection. DLP

    Dose length product (DLP) will be recorded.

    Measured: Periprocedural

  35. Impact of patients' BMI on the dose delivered to patients: Cranial CT with contrast injection. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  36. Impact of patients' BMI on the dose delivered to patients: Cranial CT with contrast injection. Acquisition parameters, kV

    Acquisition parameters (kV)will be recorded

    Measured: Periprocedural

  37. Impact of patients' BMI on the dose delivered to patients: Cranial CT with contrast injection. Acquisition parameters, mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  38. Impact of patients' BMI on the dose delivered to patients: Cranial CT with contrast injection. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  39. Impact of patients' BMI on the dose delivered to patients: Cranial CT with contrast injection. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  40. Impact of reconstruction algorithms on the dose delivered to patients : Cranial CT with contrast injection. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  41. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Supra-aortic trunk CT. Acquisition type

    The type of acquisition will be recorded

    Measured: Periprocedural

  42. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Supra-aortic trunk CT. Number of acquisitions

    The number of acquisitions will be recorded

    Measured: Periprocedural

  43. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Supra-aortic trunk CT. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  44. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Supra-aortic trunk CT. DLP

    The dose (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  45. Impact of patients' BMI on the dose delivered to patients : Supra-aortic trunk CT. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  46. Impact of patients' BMI on the dose delivered to patients : Supra-aortic trunk CT. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  47. Impact of patients' BMI on the dose delivered to patients : Supra-aortic trunk CT. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  48. Impact of patients' BMI on the dose delivered to patients : Supra-aortic trunk CT. Acquisition parameters. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  49. Impact of patients' BMI on the dose delivered to patients : Supra-aortic trunk CT. Acquisition parameters. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  50. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Neck and ear, nose and throat sphere CT with contrast injection. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  51. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Neck and ear, nose and throat sphere CT with contrast injection. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  52. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Neck and ear, nose and throat sphere CT with contrast injection. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  53. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Neck and ear, nose and throat sphere CT with contrast injection. DLP

    The dose (DLP) expressed in mGy.cm will be recorded

    Measured: Periprocedural

  54. Impact of patients' BMI on the dose delivered to patients : Neck and ear, nose and throat sphere CT with contrast injection. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  55. Impact of reconstruction algorithms on the dose delivered to patients : Neck and ear, nose and throat sphere CT with contrast injection. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  56. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological abdomen-pelvis CT scan. Acquisition type

    The type of acquisitions will be recorded.

    Measured: Periprocedural

  57. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological abdomen-pelvis CT scan. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  58. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological abdomen-pelvis CT scan. CTDIvol

    The dose (CDTIvol) will be recorded.

    Measured: Periprocedural

  59. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological abdomen-pelvis CT scan. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded

    Measured: Periprocedural

  60. Impact of patients' BMI on the dose delivered to patients : Oncological abdomen-pelvis CT scan. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  61. Impact of patients' BMI on the dose delivered to patients : Oncological abdomen-pelvis CT scan. Acquisition parameters (kV)

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  62. Impact of patients' BMI on the dose delivered to patients : Oncological abdomen-pelvis CT scan. Acquisition parameters (mAs)

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  63. Impact of patients' BMI on the dose delivered to patients : Oncological abdomen-pelvis CT scan. Acquisition parameters. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  64. Impact of patients' BMI on the dose delivered to patients : Oncological abdomen-pelvis CT scan. Acquisition parameters. Helical pitch

    Helical pitch will be recorded will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  65. Impact of reconstruction algorithms on the dose delivered to patients: Oncological abdomen-pelvis CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  66. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Abdomen-pelvis CT scan to check for kidney stones. Acquisition type an

    The type of acquisition will be recorded.

    Measured: Periprocedural

  67. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Abdomen-pelvis CT scan to check for kidney stones. Number of acquisitions an

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  68. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Abdomen-pelvis CT scan to check for kidney stones. CTDIvol an

    The dose (CDTIvol) will be recorded.

    Measured: Periprocedural

  69. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Abdomen-pelvis CT scan to check for kidney stones. DLP an

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  70. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan to check for kidney stones. BMI an

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  71. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan to check for kidney stones. Acquisition parameters. Kv an

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  72. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan to check for kidney stones. Acquisition parameters. mAs an

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  73. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan to check for kidney stones. Rotation time an

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  74. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan to check for kidney stones. Helical pitch an

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  75. Impact of reconstruction algorithms on the dose delivered to patients : Abdomen-pelvis CT scan to check for kidney stones. Type of reconstruction algorithm an

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  76. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  77. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  78. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  79. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  80. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  81. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  82. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  83. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  84. Impact of patients' BMI on the dose delivered to patients : Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  85. Impact of reconstruction algorithms on the dose delivered to patients : Abdomen-pelvis CT scan for non-oncological purposes and to check for kidney stones. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  86. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological chest-abdomen-pelvis CT scan. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  87. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological chest-abdomen-pelvis CT scan. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  88. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological chest-abdomen-pelvis CT scan. CTDIvol

    The dose (CDTIvol) will be recorded.

    Measured: Periprocedural

  89. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological chest-abdomen-pelvis CT scan. DLP

    The dose (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  90. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen-pelvis CT scan. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  91. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen-pelvis CT scan. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  92. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen-pelvis CT scan. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  93. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen-pelvis CT scan. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  94. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen-pelvis CT scan. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  95. Impact of reconstruction algorithms on the dose delivered to patients : Oncological chest-abdomen-pelvis CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  96. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Non-oncological chest-abdomen-pelvis CT scan. Acquisition type.

    The type of acquisition will be recorded.

    Measured: Periprocedural

  97. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Non-oncological chest-abdomen-pelvis CT scan. Number of acquisitions.

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  98. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Non-oncological chest-abdomen-pelvis CT scan. CDTIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  99. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Non-oncological chest-abdomen-pelvis CT scan. CDTIvol. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  100. Impact of patients' BMI on the dose delivered to patients : Non-oncological chest-abdomen-pelvis CT scan. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  101. Impact of patients' BMI on the dose delivered to patients : Non-oncological chest-abdomen-pelvis CT scan. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  102. Impact of patients' BMI on the dose delivered to patients : Non-oncological chest-abdomen-pelvis CT scan. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  103. Impact of patients' BMI on the dose delivered to patients : Non-oncological chest-abdomen-pelvis CT scan. Acquisition parameters. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  104. Impact of patients' BMI on the dose delivered to patients : Non-oncological chest-abdomen-pelvis CT scan. Acquisition parameters. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  105. Impact of reconstruction algorithms on the dose delivered to patients : Non-oncological chest-abdomen-pelvis CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  106. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological chest-abdomen CT scan. Aquisition type

    The type of acquisitions will be recorded.

    Measured: Periprocedural

  107. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological chest-abdomen CT scan. Number of aquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  108. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological chest-abdomen CT scan. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  109. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Oncological chest-abdomen CT scan. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  110. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen CT scan. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  111. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen CT scan. Acquisition parameters (kV)

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  112. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen CT scan. Acquisition parameters (mAs)

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  113. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen CT scan. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  114. Impact of patients' BMI on the dose delivered to patients : Oncological chest-abdomen CT scan. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  115. Impact of reconstruction algorithms on the dose delivered to patients : Oncological chest-abdomen CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  116. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Non-oncological chest-abdomen CT scan. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  117. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Non-oncological chest-abdomen CT scan. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  118. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Non-oncological chest-abdomen CT scan. CTDIvol

    The dose (CDTIvol) will be recorded.

    Measured: Periprocedural

  119. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Non-oncological chest-abdomen CT scan. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  120. Impact of patients' BMI on the dose delivered to patients : Non-oncological chest-abdomen CT scan

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  121. Impact of patients' BMI on the dose delivered to patients : Non-oncological chest-abdomen CT scan. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  122. Impact of patients' BMI on the dose delivered to patients : Non-oncological chest-abdomen CT scan. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  123. Impact of reconstruction algorithms on the dose delivered to patients: Non-oncological chest-abdomen CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  124. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lower limb angiography. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  125. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lower limb angiography. Number of acquitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  126. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lower limb angiography. CTDIvol

    The dose CDTIvol) will be recorded.

    Measured: Periprocedural

  127. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lower limb angiography. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  128. Impact of patients' BMI on the dose delivered to patients : Lower limb angiography. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  129. Impact of patients' BMI on the dose delivered to patients : Lower limb angiography. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  130. Impact of patients' BMI on the dose delivered to patients : Lower limb angiography. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  131. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lower limb angiography. Rotation time

    Rotation time will be recorded in seconds.

    Measured: Periprocedural

  132. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lower limb angiography. Helical pitch

    Helical pitch will be recorded as a ratio.This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  133. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lower limb angiography. Type of reconstruction algorithm

    Type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  134. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Cervical spine CT scan. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  135. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Cervical spine CT scan. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  136. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Cervical spine CT scan. CDTIvol

    The dose (CDTIvol) will be recorded.

    Measured: Periprocedural

  137. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Cervical spine CT scan. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  138. Impact of patients' BMI on the dose delivered to patients : Cervical spine CT scan. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  139. Impact of patients' BMI on the dose delivered to patients : Cervical spine CT scan. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  140. Impact of patients' BMI on the dose delivered to patients : Cervical spine CT scan. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  141. Impact of patients' BMI on the dose delivered to patients : Cervical spine CT scan. Acquisition parameters. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  142. Impact of patients' BMI on the dose delivered to patients : Cervical spine CT scan. Acquisition parameters. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  143. Impact of reconstruction algorithms on the dose delivered to patients : Cervical spine CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  144. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Thoracic spine CT scan. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  145. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Thoracic spine CT scan. Number of acquisitions

    The number of acquisition will be recorded.

    Measured: Periprocedural

  146. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Thoracic spine CT scan. CTDIvol

    The dose (CDTIvol) will be recorded.

    Measured: Periprocedural

  147. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Thoracic spine CT scan. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  148. Impact of patients' BMI on the dose delivered to patients : Thoracic spine CT scan. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  149. Impact of patients' BMI on the dose delivered to patients : Thoracic spine CT scan. Acquisition parameters (kV)

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  150. Impact of patients' BMI on the dose delivered to patients : Thoracic spine CT scan. Acquisition parameters (mAs)

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  151. Impact of patients' BMI on the dose delivered to patients : Thoracic spine CT scan. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  152. Impact of patients' BMI on the dose delivered to patients : Thoracic spine CT scan. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  153. Impact of reconstruction algorithms on the dose delivered to patients : Thoracic spine CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  154. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lumbar spine CT scan. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  155. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lumbar spine CT scan. Number of acquisitions

    The number of acquisition will be recorded.

    Measured: Periprocedural

  156. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lumbar spine CT scan. CTDIvol

    The dose (CDTIvol) will be recorded.

    Measured: Periprocedural

  157. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Lumbar spine CT scan. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded

    Measured: Periprocedural

  158. Impact of patients' BMI on the dose delivered to patients : Lumbar spine CT scan. BMI

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  159. Impact of patients' BMI on the dose delivered to patients : Lumbar spine CT scan. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  160. Impact of patients' BMI on the dose delivered to patients : Lumbar spine CT scan. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  161. Impact of patients' BMI on the dose delivered to patients : Lumbar spine CT scan. Acquisition parameters. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  162. Impact of patients' BMI on the dose delivered to patients : Lumbar spine CT scan. Acquisition parameters. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  163. Impact of reconstruction algorithms on the dose delivered to patients: Lumbar spine CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  164. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Pelvis CT scan. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  165. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Pelvis CT scan. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  166. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Pelvis CT scan. CTDIvol

    The dose (CDTIvol) will be recorded.

    Measured: Periprocedural

  167. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Pelvis CT scan. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded.

    Measured: Periprocedural

  168. Impact of patients' BMI on the dose delivered to patients : Pelvis CT scan. BMI.

    Weight and height will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  169. Impact of patients' BMI on the dose delivered to patients : Pelvis CT scan. Acquistion parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  170. Impact of patients' BMI on the dose delivered to patients : Pelvis CT scan. Acquistion parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  171. Impact of patients' BMI on the dose delivered to patients : Pelvis CT scan. Acquistion parameters. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  172. Impact of patients' BMI on the dose delivered to patients : Pelvis CT scan. Acquistion parameters. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  173. Impact of reconstruction algorithms on the dose delivered to patients : Pelvis CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

  174. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Extremities CT scan. Acquisition type

    The type of acquisition will be recorded.

    Measured: Periprocedural

  175. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Extremities CT scan. Number of acquisitions

    The number of acquisitions will be recorded.

    Measured: Periprocedural

  176. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Extremities CT scan. CTDIvol

    The dose (CTDIvol) will be recorded.

    Measured: Periprocedural

  177. Impact of the spectral acquisition/detection technique on the dose delivered to patients: Extremities CT scan. DLP

    The dose length product (DLP) expressed in mGy.cm will be recorded

    Measured: Periprocedural

  178. Impact of patients' BMI on the dose delivered to patients : Extremities CT scan. BMI

    Weight in kg and height in cm in will be combined to report BMI in kg/m^2

    Measured: Periprocedural

  179. Impact of patients' BMI on the dose delivered to patients : Extremities CT scan. Acquisition parameters. kV

    Acquisition parameters (kV) will be recorded

    Measured: Periprocedural

  180. Impact of patients' BMI on the dose delivered to patients : Extremities CT scan. Acquisition parameters. mAs

    Acquisition parameters (mAs) will be recorded

    Measured: Periprocedural

  181. Impact of patients' BMI on the dose delivered to patients : Extremities CT scan. Acquisition parameters. Rotation time

    Rotation time will be recorded in seconds

    Measured: Periprocedural

  182. Impact of patients' BMI on the dose delivered to patients : Extremities CT scan. Acquisition parameters. Helical pitch

    Helical pitch will be recorded as a ratio. This represents the relationship between patient couch movement and X-ray beam width. It is the distance travelled by the table during one 360 degree gantry rotation divided by the collimated section thickness

    Measured: Periprocedural

  183. Impact of reconstruction algorithms on the dose delivered to patients: Extremities CT scan. Type of reconstruction algorithm

    The type of reconstruction algorithm (iterative or deep learning) will be recorded

    Measured: Periprocedural

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Dec 2025
  2. Study start1 Sep 2025
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion30 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
9,600 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07305103
Sponsor's protocol ID
NIMAO/2024-1/DD-01
Acronym
NR Spectral
Status last verified
Oct 2026
First submitted
10 Sep 2025
Last updated
21 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Henzler T, Fink C, Schoenberg SO, Schoepf UJ. Dual-energy CT: radiation dose aspects. AJR Am J Roentgenol. 2012 Nov;199(5 Suppl):S16-25. doi: 10.2214/AJR.12.9210.

    PubMed 23097163

  • Ghasemi Shayan R, Oladghaffari M, Sajjadian F, Fazel Ghaziyani M. Image Quality and Dose Comparison of Single-Energy CT (SECT) and Dual-Energy CT (DECT). Radiol Res Pract. 2020 Apr 20;2020:1403957. doi: 10.1155/2020/1403957. eCollection 2020.

    PubMed 32373363

  • Greffier J, Villani N, Defez D, Dabli D, Si-Mohamed S. Spectral CT imaging: Technical principles of dual-energy CT and multi-energy photon-counting CT. Diagn Interv Imaging. 2023 Apr;104(4):167-177. doi: 10.1016/j.diii.2022.11.003. Epub 2022 Nov 19.

    PubMed 36414506

  • Dabli D, Frandon J, Belaouni A, Akessoul P, Addala T, Berny L, Beregi JP, Greffier J. Optimization of image quality and accuracy of low iodine concentration quantification as function of dose level and reconstruction algorithm for abdominal imaging using dual-source CT: A phantom study. Diagn Interv Imaging. 2022 Jan;103(1):31-40. doi: 10.1016/j.diii.2021.08.004. Epub 2021 Oct 6.

    PubMed 34625394

  • Si-Mohamed SA, Boccalini S, Villien M, Yagil Y, Erhard K, Boussel L, Douek PC. First Experience With a Whole-Body Spectral Photon-Counting CT Clinical Prototype. Invest Radiol. 2023 Jul 1;58(7):459-471. doi: 10.1097/RLI.0000000000000965. Epub 2023 Feb 22.

    PubMed 36822663

  • Wortman JR, Shyu JY, Dileo J, Uyeda JW, Sodickson AD. Dual-energy CT for routine imaging of the abdomen and pelvis: radiation dose and image quality. Emerg Radiol. 2020 Feb;27(1):45-50. doi: 10.1007/s10140-019-01733-9. Epub 2019 Nov 1.

    PubMed 31673838

  • Noda Y, Kawai N, Kawamura T, Kobori A, Miyase R, Iwashima K, Kaga T, Miyoshi T, Hyodo F, Kato H, Matsuo M. Radiation and iodine dose reduced thoraco-abdomino-pelvic dual-energy CT at 40 keV reconstructed with deep learning image reconstruction. Br J Radiol. 2022 Jun 1;95(1134):20211163. doi: 10.1259/bjr.20211163. Epub 2022 Mar 4.

    PubMed 35230135

  • Etard C, Bigand E, Salvat C, Vidal V, Beregi JP, Hornbeck A, Greffier J. Patient dose in interventional radiology: a multicentre study of the most frequent procedures in France. Eur Radiol. 2017 Oct;27(10):4281-4290. doi: 10.1007/s00330-017-4780-5. Epub 2017 Mar 13.

    PubMed 28289939

  • Greffier J, Ferretti G, Rousseau J, Andreani O, Alonso E, Rauch A, Gillet R, Le Roy J, Cabrol-Faivre L, Douane F, David A, Henry S, Jacques T, Stefanovic X, Decoux E, Lafay F, Pilleul F, Couzon F, Boutet C, Woerly B, Baur P, Sans N, Faruch M, Moussier-Lherm A, Tselikas L, Jacquier A, Bigand E, Pessis E, Teriitehau C, Magnier F, Cassagnes L, Haberlay M, Boutteau D, De Kerviler E, Majorel-Gouthain C, Defez D, Vuillod A, Rouviere O, Hennequin L, Fohlen A, Alwan R, Malakhia A, Aubry S, Dohan A, Eresue-Bony M, Gautier R, Dal R, Dabli D, Hebert T, Kovacs R, Hadid-Beurrier L, Bousson V, Potel M, Barbotteau Y, Michel C, Habib-Geryes B, Andre M, Arnaud T, Bestion N, Ernst O, Monfraix S, Brillet PY, Guiu B, Boussel L, Demonchy M, Beregi JP, Frandon J. National dose reference levels in computed tomography-guided interventional procedures-a proposal. Eur Radiol. 2020 Oct;30(10):5690-5701. doi: 10.1007/s00330-020-06903-9. Epub 2020 May 2.

    PubMed 32361774

Questions about this trial

What is this clinical trial studying?

An observational study of Medical Imaging, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dosimetric reference levels for spectral computed tomography examinations in France: Chest CT for pulmonary embolism. CTDIvol (time frame: Periprocedural). The study lists 38 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07305103, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in